Pyxis Oncology (PYXS) Current Deferred Revenue (2023)
Pyxis Oncology's (PYXS) quarterly Current Deferred Revenue came in at $7.7 million in Q4 2023, up 6.39% on a QoQ basis from $7.2 million in Q3 2023.
Pyxis Oncology (PYXS) Current Deferred Revenue (2023) Analysis & Trends
Pyxis Oncology (PYXS) has 1 years of Current Deferred Revenue data on file, last reported at $7.7 million in Q4 2023.
- On a quarterly basis, Current Deferred Revenue changed N/A year-over-year to $7.7 million in Q4 2023; TTM through Dec 2023 was $7.7 million, a N/A change from a year earlier, with the FY2023 full-year figure at $7.7 million, changed N/A from the prior year.
- Current Deferred Revenue for Q4 2023 stood at $7.7 million, up from $7.2 million in the prior quarter.
- Over the last five years, Current Deferred Revenue for PYXS reached as high as $7.7 million in Q4 2023 and fell as low as $7.2 million in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Pyxis Oncology | 166.54 Mn | 99.69 Mn | 8.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 7.66 Mn |
| Sep 30, 2023 | 7.20 Mn |